Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 1/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.36 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.36 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27191841 | 0.80 | PDE4A (0.36) | PDE4APDE4BPDE4CPDE4DCYP1A2 | |
| SCHEMBL27191761 | 0.75 | RPS6KA5 (0.40) | RPS6KA5 | |
| SCHEMBL31580070 | 0.74 | SMN1; SMN2 (0.40) | RPS6KA5 | |
| SCHEMBL27192413 | 0.73 | RPS6KA5 (0.35) | RPS6KA5 | |
| SCHEMBL27192285 | 0.69 | RPS6KA5 (0.32) | RPS6KA5 | |
| SCHEMBL30702021 | 0.69 | RPS6KA5 (0.32) | RPS6KA5 | |
| SCHEMBL27192343 | 0.69 | PARP1 (0.36) | PDE4APDE4BPDE4CPDE4DRPS6KA5 | |
| SCHEMBL30298911 | 0.68 | CYP1A2 (0.47) | CYP1A2 | |
| SCHEMBL4760413 | 0.68 | ATM (0.51) | RPS6KA5HTT | |
| SCHEMBL27191997 | 0.67 | TLR7 (0.39) | PDE4APDE4BPDE4CPDE4DRPS6KA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12410183-B2 | Sars-cov2 main protease inhibitors | GILEAD SCIENCES, INC. (US) | 2025-09-09 | — | — | US | disclosed |
| EP-4565574-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2025-06-11 | — | — | EP | disclosed |
| CN-119731159-A | SARS-CoV2 main proteinase inhibitor | 吉利德科学公司 | 2025-03-28 | — | — | CN | disclosed |
| US-20250042915-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | GILEAD SCIENCES, INC. | 2025-02-06 | — | — | US | disclosed |
| US-12091420-B2 | SARS-COV2 main protease inhibitors | GILEAD SCIENCES, INC. (US) | 2024-09-17 | — | — | US | disclosed |
| US-20240239807-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | GILEAD SCIENCES, INC. | 2024-07-18 | — | — | US | disclosed |
| US-20240116946-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | GILEAD SCIENCES, INC. | 2024-04-11 | — | — | US | disclosed |
| WO-2024031089-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2024-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250042915-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | ACE2, TMPRSS2, ACE | PDE4A 4087/4885PDE4B 3665/4885PDE4C 4263/4885 |
| US-12091420-B2 | SARS-COV2 main protease inhibitors | ACE2, TMPRSS2, ACE | PDE4A 4087/4885PDE4B 3665/4885PDE4C 4263/4885 |
| US-20240116946-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | ACE2, TMPRSS2, ACE | PDE4A 4087/4885PDE4B 3665/4885PDE4C 4263/4885 |
| US-12410183-B2 | Sars-cov2 main protease inhibitors | ACE2, TMPRSS2, ACE | PDE4A 4087/4885PDE4B 3665/4885PDE4C 4263/4885 |
| US-20240239807-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | ACE2, TMPRSS2, ACE | PDE4A 4087/4885PDE4B 3665/4885PDE4C 4263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.